Previous Article | Next Article ![]()
Journal of Virology, November 2001, p. 11239-11243, Vol. 75, No. 22
Laboratory of Persistent Viral
Diseases1 and Microscopy
Branch,2 National Institute of Allergy and
Infectious Diseases, Rocky Mountain Laboratories, Hamilton,
Montana 59840
Received 4 December 2000/Accepted 18 August 2001
Glycosylated Gag (Glycogag) is a transmembrane protein encoded by
murine and feline oncornaviruses. While the protein is dispensible for
virus replication, Glycogag-null mutants of a neurovirulent murine
oncornavirus are slow to spread in vivo and exhibit a loss of
pathogenicity. The function of this protein in the virus life cycle,
however, is not understood. Glycogag is expressed at the plasma
membrane of infected cells but has not been detected in virions. In the
present study we have reexamined this issue and have found an
N-terminal cleavage fragment of Glycogag which was pelleted by
high-speed centrifugation and sedimented in sucrose density gradients
at the same bouyant density as virus particles. Its association with
virions was confirmed by velocity sedimentation through iodixanol,
which effectively separated membrane microvesicles from virus
particles. Furthermore, the apparent molecular weight of the
virion-associated protein was different from that of the protein
extracted from the plasma membrane, suggesting some level of
specificity or selectivity of incorporation.
Glycosylated Gag (Glycogag) is an
accessory protein of murine and feline oncornaviruses (4, 6, 12,
20). It is dispensable for virus replication (2, 7, 17,
21) but appears to be an important virulence determinant
(2, 17). The protein is translated from an alternate
initiation codon upstream and in frame with the initiation codon for
pr65gag (18), the precursor of the
core proteins of the virus. The precursor of Glycogag,
pr75gag, consists of the sequence of
pr65gag but with a unique N terminus of 8 to 10 kDa (4, 5, 19). pr65gag is
synthesized as a cytosolic protein which is incorporated into virions
and processed by the viral protease into the various components of the
viral core. p75gag is synthesized at the
endoplasmic reticulum as a type II integral membrane protein
(Ncyto Cexo); is N glycosylated to an 85-kDa protein, gp85gag; and is expressed at the plasma
membrane. The majority of the unique N-terminal sequence constitutes
the cytoplasmic tail of the protein.
Our interest in Glycogag stems from evidence that it is an important
determinant of neuroinvasiveness (17). The murine
retrovirus CasFrKP (abbreviated KP), a derivative of the
wild mouse ecotropic virus CasBrE, is neuroinvasive after
intraperitoneal inoculation of neonates and causes a paralytic disease
associated with spongiform neurodegeneration (17). When
the Kozak consensus sequence (11) surrounding the
initiation codon of Glycogag was altered to knock out expression of the
protein, the mutant virus, abbreviated KPgg We have shown previously that the Glycogag protein of the virus KP is
cleaved, presumably by a cellular protease, near the middle of the
molecule. The C-terminal fragment, which contains much of the viral
capsid (CA) and nucleocapsid sequences shared with
pr65gag, is secreted, whereas the N-terminal
fragment, which contains the cytoplasmic tail, transmembrane domain,
and sequences of the matrix protein and pp12gag,
remains associated with the cell as an integral membrane protein (8). It is this N-terminal fragment which is displayed at
the plasma membrane (Fig. 1A).
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.22.11239-11243.2001
N-Terminal Cleavage Fragment of Glycosylated Gag Is
Incorporated into Murine Oncornavirus Particles
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
,
was no longer neuroinvasive (16, 17). Though Glycogag-null mutants still replicated, the kinetics of spread in vivo was measurably slower than that of wild-type virus (2, 17).

View larger version (32K):
[in a new window]
FIG. 1.
Immunoblot analysis of Gag proteins in culture
supernatants from KP- and KPgg
-infected
M. dunni fibroblasts. Supernatants from infected cells were
subjected to ultracentrifugation as described in the text to pellet
virus particles. Samples extracted with SDS sample buffer included the
supernatant fluid before centrifugation (Pre-spin), the
postcentrifugation high-speed pellet (HS Pellet), and the
postcentrifugation supernatant (HS Sup). The blot was developed first
with a rabbit antiserum to viral CA protein (B) which has been shown
previously to react with both the CA protein and shared sequences in
the secreted C-terminal fragment of Glycogag (8) (A). The
CA protein band was prominent in the Prespin and HS Pellet of both KP
and KPgg
. A similar distribution was
seen for pr40gag, an intermediate cleavage
product of the pr65gag polyprotein. These two
proteins therefore were pelleted. In contrast, the secreted fragment of
Glycogag was seen in the Pre-spin of KP but not
KPgg
and was concentrated in the HS
Sup. This result is consistent with this protein not being associated
with pelleted virions. The anti-CA antibody was then eluted from the
blot, and the blot was reprobed with an antiserum specific for Glycogag
(C). This antibody reacts with the N-terminal transmembrane protein of
Glycogag but does not react with any of the constituents of the viral
core derived from the pr65gag polyprotein (A).
Two major bands are seen only in the HS Pellet of the KP virus,
suggesting that these species may be associated with virions. Unlike
the CA and pr40gag bands in panel B, the
Glycogag bands were not seen in the Pre-spin (see the text). MA, matrix
protein; TM, transmembrane domain.
Previous studies have concluded that Glycogag is not incorporated into virions (1, 4, 15). We have reexamined this issue using an antiserum specific for an octadecapeptide (designated 4210) located at the extreme N terminus of the cytoplasmic tail (8, 16). This antiserum, designated anti-Glycogag, is specific for Glycogag and reacts with both the precursor protein and the N-terminal cleavage fragment displayed at the plasma membrane (Fig. 1A). It does not react with pr65gag or any of its cleavage products (8).
Our first approach was to ask whether Glycogag was pelleted by
high-speed centrifugation using the Glycogag-null virus
KPgg
(17) as a negative control
(Fig. 1B and C). Culture supernatants collected from Mus
dunni fibroblasts infected with either KP or KPgg
viruses were precentrifuged at
5,900 × g followed by filtration with
0.22-µm-pore-size Millex GS filters (Millipore) to remove cell
debris. One milliliter of each filtered supernatant was removed and
mixed with 0.25 ml of 5× sodium dodecyl sulfate (SDS) sample buffer
(Fig. 1, Pre-spin). Twenty milliliters was centrifuged at
187,000 × g for 2 h to pellet the virions. One
milliliter of the high-speed supernatant was also mixed with 0.25 ml of
5× SDS sample buffer (Fig. 1, HS Sup). The pellet was lysed with 1.0 ml of 1× SDS sample buffer and sonicated (Fig. 1, HS Pellet). All
samples were boiled, and 20 µl of each was separated by SDS-9% polyacrylamide gel electrophoresis. The gel was electroblotted onto an
Immobilon-P membrane (Millipore). The blot was incubated first with
rabbit anti-CA, reactive with both the C-terminal secreted fragment of
Glycogag and the CA protein of the viral core (Fig. 1B). Reactivity was
revealed with horseradish peroxidase-anti-rabbit immunoglobulin G
(IgG) (Biorad) followed by ECL chemiluminescent substrate (Amersham)
(Fig. 1). Anti-CA detected a protein of ~45 kDa with minor species of
35 to 40 kDa in the HS Sup of KP- but not
KPgg
-infected cells (Fig. 1A). These bands
represent secreted C-terminal proteolytic cleavage products of the
gp85gag precursor of Glycogag described
previously (8). Anti-CA reacted with CA protein (p30) in
the HS pellet of both viruses as well as a band of ~40 kDa which
likely represents pr40gag, an intermediate
cleavage product of pr65gag which contains both
CA and nucleocapsid proteins (22). This experiment showed
that the C-terminal fragment of Glycogag was likely not associated with
virus particles.
After the anti-CA was stripped off the blot with 2% SDS at 70°C, the
blot was reprobed with rabbit anti-Glycogag (Fig. 1C). Two major bands
ranging from ~35 to 50 kDa were detected in the HS pellet of KP but
not KPgg
. These bands represent
N-terminal cleavage fragments of Glycogag having different C termini.
They appear not to be different glycoforms, since digestion with
N-glycosidase F (PNGase; New England Biolabs) to
remove N-linked sugars resulted in a shift down in the molecular weight
of both bands (not shown). Their appearance in the HS pellet suggests that the N-terminal fragment of Glycogag may be associated with virions. It should also be noted that these bands were not observed in the prespin track even though this same material contained detectable CA protein (p30) (Fig. 1B). This suggests that if Glycogag was associated with virions, the relative quantity must be low.
To further examine the question of whether this protein was
incorporated into virus particles, KP and KPgg
viruses were subjected to equilibrium centrifugation through a 15 to
60% sucrose density gradients. The fractions were assayed by dot
blotting and probed with anti-CA to identify virion cores and, after
stripping, anti-Glycogag (Fig. 2).
Glycogag cosedimented with KP virions at a density of 1.14 to 1.17 g/ml.
|
It is well-known that buoyant density alone is not sufficient to
conclude that a protein is incorporated into virus particles (13). Microvesicles derived from the plasma membrane of
infected cells can incorporate both cytosolic and membrane proteins and can sediment at densities comparable to that of retroviruses (3, 9). Thus, it was necessary to pursue this question using
different techniques. As a first approach, we compared the
electrophoretic mobilities of Glycogag species derived from the
cell surface with that present in gradient-purified virion extracts.
Proteins at the plasma membrane of KP- or
KPgg
-infected M. dunni cells were
labeled with NHSS-S-biotin (Pierce Chemical) at 0°C
as described previously (8). After lysis with 0.5% NP-40
in 0.01 M Tris-HCl-0.15 N NaCl-0.001 M EDTA (pH 7.2) (TNE), the
lysates were divided equally. One half was boiled in SDS (Fig.
3, Total Cell Lysate). The other half was
incubated with immobilized streptavidin (Ultralink; Pierce Chemical) to isolate the biotinylated proteins prior to boiling in SDS (Fig. 3, Cell
Surface). The virion lysates (Fig. 3) were prepared using the peak
fraction from viruses purified by sucrose density gradient centrifugation. Samples were separated by SDS-polyacrylamide gel electrophoresis, blotted as for Fig. 1, and probed with anti-Glycogag antiserum. The total cell lysate of KP-infected cells contained two
predominent species of Glycogag, one above and one below the 45-kDa
marker (Fig. 3). As shown previously, the predominant species found at
the cell surface consisted of an ~50-kDa band (8), which
corresponded to the upper band of the total cell lysate. In contrast,
the virion fraction contained a predominant species corresponding to
the lower band of the total cell lysate. This lower band was also
represented at low levels in the cell surface fraction. This difference
suggests that the Glycogag sedimenting at 1.14 to 1.17 g/ml did not
represent a random sampling of the plasma membrane protein but instead
represented a subpopulation. This suggests, but certainly does not
prove, that a portion of the Glycogag detected in the virion peak
likely was associated with virions.
|
Two approaches to separating virions from plasma membrane microvesicles
have been described. Ott et al. (14) have used a protease
digestion technique followed by sedimentation through sucrose. This
procedure has had great utility in identifying proteins which are
inside virions and protected from the protease. However, the bulk of
the N-terminal cleavage fragment of Glycogag is exposed externally and
would be subject to protease digestion. Only the cytosolic tail and
transmembrane domain (~88 amino acid residues in the case of the
virus KP) should be protease resistant. We chose, therefore, an
alternate technique which relies on velocity sedimentation through
iodixanol (Optiprep) to separate virions from plasma membrane
microvesicles (3, 10). Briefly, 8 ml of supernatant fluid
from KP-infected M. dunni cells was precleared at
1,500 × g, filtered through a 0.22-µm-pore-size
Millex GS filter, and centrifuged for 2 h at 100,000 × g through a 20% sucrose cushion. The pellet was suspended in TNE,
layered onto an 11-ml linear 6 to 18% iodixanol (Nycomed) gradient,
and centrifuged for 1 h 20 min at 187,000 × g.
Fractions (0.5 ml) were removed from the top of the gradient and
analyzed by dot blotting. The blot was probed sequentially with three
different antibodies to virus-encoded proteins (CA, Glycogag, and
transmembrane protein/p15E), each antibody being stripped off as
described above before reprobing with the next antibody. Anti-CA
protein was developed with an alkaline phosphatase-coupled anti-rabbit
Ig and detected with a fluorescent substrate (AttoPhos; Promega) to
allow quantification on a PhosphorImager (Molecular Dynamics).
Anti-Glycogag and anti-p15E (kindly provided by (Garhard Hunsmann,
Gottingen, Germany) were developed using horseradish
peroxidase-anti-rabbit Ig followed by ECL (Amersham) substrate and
were detected on film (Fig. 4). The peak
of CA immunoreactivity was seen near the bottom of the gradient,
marking the location of virus particles. There were two peaks of
Glycogag immunoreactivity, one located in fractions 4 to 9, likely
representing membrane microvesicles devoid of CA protein, and a second
peak coincident with the virion peak near the bottom of the gradient.
Interestingly, a similar distribution with two peaks was seen for p15E.
Thus, Glycogag, like another transmembrane protein, p15E, was found in
plasma membrane microvesicles but was also readily detectable in virion
fractions, suggesting again that this protein is incorporated into
virus particles.
|
This then raises the question of whether Glycogag is specifically concentrated in virus particle membranes, as might be expected for a viral structural protein. If one compares the relative distributions of p15E and Glycogag in the gradient (Fig. 4), it is apparent that p15E is partitioned predominantly, though admittedly not dramatically so, in the virion fractions. On the other hand, a larger fraction of Glycogag appeared to partition in the vesicular fractions. Though this could be simply a consequence of differences in the distribution of the two proteins in the plasma membrane, this difference could also indicate that Glycogag was not selectively concentrated in virions and that its presence in virions was a function of a passive rather than an active process. Indeed, there is now abundant evidence for passive incorporation of normal cellular membrane proteins into retroviral envelopes, indicating that the selective exclusion of cell membrane proteins during virus assembly is relatively weak (10). It should be reiterated, however, that the difference in apparent molecular weight between cell surface Glycogag and the Glycogag in virion fractions derived from equilibrium sedimentation experiments (Fig. 3) suggests some level of selectivity.
What role, if any, this virion-associated component could have in the virus life cycle is a matter of pure speculation at this point. It is of interest, in this regard, that Fan et al. (7) noted a small difference in the buoyant densities of Glygag-null and wild-type Moloney murine leukemia virus (1.185 versus 1.170 g/ml, respectively) and suggested that the protein may be involved in viral morphogenesis. This difference in buoyant densities was not observed in the current study. However, this could have been a consequences of technical differences and certainly warrants reexamination. It is also possible that Glycogag interacts with a coreceptor on host cells which could enhance viral infectivity and thus promote viral spread.
Although Glycogag is dispensable for virus replication, it is clear that its expression in infected cells has a strong influence on virus dissemination in vivo and that it plays a critical role in viral virulence. Understanding the nature of this effect should provide important clues to the selective forces driving expression of this protein (16) as well as insight into the virus-host interactions which ultimately lead to the induction of disease.
| |
ACKNOWLEDGMENTS |
|---|
We thank Gary Hettrick of the RML Graphics Department for figure reproductions.
R. Fujisawa was the recipient of a JSPS Research Fellowship for Japanese Biological and Behavioral Researchers at the National Institutes of Health (69607).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, 903 S. 4th St., Hamilton, MT 59840. Phone: (406) 363-9339. Fax: (406) 363-9286. E-mail: jportis{at}nih.gov.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Aoki, T.,
E. A. Boyse,
L. J. Old,
E. DeHarven,
U. Hammerling, and H. A. Wood.
1970.
G (Gross) and H-2 cell-surface antigens: location on Gross leukemia cells by electron microscopy with visually labeled antibody.
Proc. Natl. Acad. Sci. USA
65:569-576 |
| 2. |
Corbin, A.,
A. C. Prats,
J.-L. Darlix, and M. Sitbon.
1994.
A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses.
J. Virol.
68:3857-3867 |
| 3. |
Dettenhofer, M., and X. F. Yu.
1999.
Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions.
J. Virol.
73:1460-1467 |
| 4. |
Edwards, S. A., and H. Fan.
1979.
gag-related polyproteins of Moloney murine leukemia virus: evidence for independent synthesis of glycosylated and unglycosylated forms.
J. Virol.
30:551-563 |
| 5. |
Edwards, S. A., and H. Fan.
1980.
Sequence relationship of glycosylated and unglycosylated gag polyproteins of Moloney murine leukemia virus.
J. Virol.
35:41-51 |
| 6. |
Evans, L. H.,
S. Dressler, and D. Kabat.
1977.
Synthesis and glycosylation of polyprotein precursors to the internal core protein of Friend murine leukemia virus.
J. Virol.
24:865-874 |
| 7. |
Fan, H.,
H. Chute,
E. Chao, and M. Feuerman.
1983.
Construction and characterization of Moloney murine leukemia virus mutants unable to synthesize glycosylated gag polyprotein.
Proc. Natl. Acad. Sci. USA
80:5965-5969 |
| 8. | Fujisawa, R., F. J. McAtee, J. H. Zirbel, and J. L. Portis. 1997. Characterization of glycosylated Gag expressed by a neurovirulent murine leukemia virus: identification of differences in processing in vitro and in vivo. J. Virol. 71:5355-5360[Abstract]. |
| 9. | Gluschankof, P., I. Mondor, H. R. Gelderblom, and Q. J. Sattentau. 1997. Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virology 230:125-133[CrossRef][Medline]. |
| 10. |
Hammarstedt, M.,
K. Wallengren,
K. W. Pedersen,
N. Roos, and H. Garoff.
2000.
Minimal exclusion of plasma membrane proteins during retroviral envelope formation.
Proc. Natl. Acad. Sci. USA
97:7527-7532 |
| 11. |
Kozak, M.
1989.
The scanning model for translation: an update.
J. Cell Biol.
108:229-241 |
| 12. | Neil, J. C., J. E. Smart, M. J. Hayman, and O. Jarrett. 1980. Polypeptides of feline leukemia virus: a glycosylated gag-related protein is released into culture fluids. Virology 105:250-253[CrossRef][Medline]. |
| 13. | Ott, D. E. 1997. Cellular proteins in HIV virions. Rev. Med. Virol. 7:167-180[CrossRef][Medline]. |
| 14. | Ott, D. E., L. V. Coren, D. G. Johnson, R. C. Sowder, L. O. Arthur, and L. E. Henderson. 1995. Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain. AIDS Res. Hum. Retroviruses 11:1003-1006[Medline]. |
| 15. |
Pillemer, E. A.,
D. A. Kooistra,
O. N. Witte, and I. L. Weissman.
1986.
Monoclonal antibody to the amino-terminal L sequence of murine leukemia virus glycosylated gag polyproteins demonstrates their unusual orientation in the cell membrane.
J. Virol.
57:413-421 |
| 16. | Portis, J. L., R. Fujisawa, and F. J. McAtee. 1996. The glycosylated gag protein of MuLV is a determinant of neuroinvasiveness: analysis of second site revertants of a mutant MuLV lacking expression of this protein. Virology 226:384-392[CrossRef][Medline]. |
| 17. |
Portis, J. L.,
G. J. Spangrude, and F. J. McAtee.
1994.
Identification of a sequence in the unique 5' open reading frame of the gene encoding glycosylated Gag which influences the incubation period of neurodegenerative disease induced by a murine retrovirus.
J. Virol.
68:3879-3887 |
| 18. | Prats, A. C., G. De Billy, P. Wang, and J. L. Darlix. 1989. CUG initiation codon used for the synthesis of a cell surface antigen coded by the murine leukemia virus. J. Mol. Biol. 205:363-372[CrossRef][Medline]. |
| 19. | Schultz, A., and S. Oroszlan. 1978. Murine leukemia virus gag polyproteins: the peptide chain unique to Pr80 is located at the amino terminus. Virology 91:481-486[CrossRef][Medline]. |
| 20. |
Schultz, A. M.,
E. H. Rabin, and S. Oroszlan.
1979.
Post-translational modification of Rauscher leukemia virus precursor polyproteins encoded by the gag gene.
J. Virol.
30:255-266 |
| 21. |
Schwartzberg, P.,
J. Colicelli, and S. P. Goff.
1983.
Deletion mutants of Moloney murine leukemia virus which lack glycosylated gag protein are replication competent.
J. Virol.
46:538-546 |
| 22. | Yoshinaka, Y., and R. B. Luftig. 1977. Characterization of Rauscher leukemia virus (RLV) P40-42, an intermediate cleavage product of the group specific antigen (gag) precursor polypeptide, P65-70. Biochem. Biophys. Res. Commun. 79:319-325[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»